On 20 June 2017, orphan designation (EU/3/17/1880) was granted by the European Commission to ChemoCentryx Limited, United Kingdom, for avacopan (also known as CCX168 or (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide) for the treatment of C3 glomerulopathy.
The sponsorship was transferred to Chemocentryx Ireland Limited, Ireland, in February 2019.
|Disease / condition||
Treatment of C3 glomerulopathy
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;